Pfizer Inc ($PFE@US)—currently known worldwide for its COVID-19 vaccine— announced it would buy Canadian cancer drugmaker, Trillium Therapeutics ($TRIL@US) for $2.26 billion. Pfizer initially purchased a $25 million stake in Trillium last year, and this most recent deal includes all outstanding shares at $18.50 each—more than a 200% premium.
